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ABSTRACT
Background
Interplays between Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB) in
human and host professional phagocytes, namely macrophages (M/s) and dendritic cells (DCs),
are central to immune protection against TB and to TB pathogenesis. We and others have
recently shown that the C-type lectin dendritic cell–specific intercellular adhesion molecule-3
grabbing nonintegrin (DC-SIGN; CD209) mediates important interactions between mycobac-
teria and human monocyte-derived DCs (MoDCs) in vitro.
Methods and Findings
In order to explore the possible role of DC-SIGN in M. tuberculosis infection in vivo, we have
analysed DC-SIGN expression in broncho-alveolar lavage (BAL) cells from patients with TB (n¼
40) or with other non-mycobacterial lung pathologies, namely asthma (n¼14) and sarcoidosis
(n¼11), as well as from control individuals (n¼9). We show that in patients with TB, up to 70%
of alveolar M/s express DC-SIGN. By contrast, the lectin is barely detected in alveolar M/s from
all other individuals. Flow cytometry, RT-PCR, and enzyme-linked immunosorbent assay
analyses of BAL-derived fluids and cells indicated that M. tuberculosis infection induces DC-SIGN
expression in alveolar M/s by a mechanism that is independent of Toll-like receptor-4,
interleukin (IL)-4, and IL-13. This mechanism most likely relies on the secretion of soluble host
and/or mycobacterial factors that have yet to be identified, as both infected and uninfected
bystander M/s were found to express DC-SIGN in the presence of M. tuberculosis.
Immunohistochemical examination of lung biopsy samples from patients with TB showed
that the bacilli concentrate in pulmonary regions enriched in DC-SIGN-expressing alveolar M/s
in vivo. Ex vivo binding and inhibition of binding experiments further revealed that DC-SIGN–
expressing alveolar M/s constitute preferential target cells for M. tuberculosis, as compared to
their DC-SIGN
  counterparts. In contrast with what has been reported previously in MoDCs in
vitro, ex vivo DC-SIGN ligation by mycobacterial products failed to induce IL-10 secretion by
alveolar M/s, and IL-10 was not detected in BALs from patients with TB.
Conclusion
Altogether, our results provide further evidence for an important role of DC-SIGN during TB
in humans. DC-SIGN induction in alveolar M/s may have important consequences on lung
colonization by the tubercle bacillus, and on pulmonary inflammatory and immune responses
in the infected host.
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Interactions between Mycobacterium tuberculosis, the airborne
agent of tuberculosis (TB) in human and host phagocytes,
namely macrophages (M/s) and dendritic cells (DCs), are
central to anti-mycobacterial immunity and to TB patho-
genesis [1,2]. In particular alveolar M/s constitute a primary
niche for the tubercle bacillus [3]. At the molecular level,
interactions between the bacillus and host phagocytes rely on
a variety of cellular receptors, among which the C-type lectin
DC-speciﬁc intercellular adhesion molecule-3 grabbing non-
integrin (DC-SIGN; CD209) has recently received particular
attention. Initially described as an HIV gp120 receptor [4,5],
DC-SIGN has afterwards been shown to allow monocyte-
derived DCs (MoDCs) to recognize a variety of microbes,
including viruses, parasites, and bacteria [6]. A set of recent
reports has established that DC-SIGN plays a key role in
mycobacteria interactions with DCs, at least in vitro [7,8].
Indeed, DC-SIGN allows human MoDCs to recognize mem-
bers of the M. tuberculosis complex through lipoarabino-
mannan (LAM), an abundant lipoglycan of the mycobacterial
envelope [7,9], and through other molecules, such lip-
omannan, arabinomannan, and the 19 kDa antigen [8]; and
DC-SIGN ligation by LAM partially inhibits the maturation of
bacterial lipopolysaccharide (LPS)-stimulated MoDCs and
potentiates the secretion of the anti-inﬂammatory cytokine
interleukin (IL)-10 by these cells [8]. DC-SIGN interactions
with mycobacteria or mycobacterial products may thus be of
beneﬁt for either the pathogen, by down-modulating DC
functions, or for the host, by limiting tissue inﬂammation and
immunopathology [11–13]. It is noteworthy that DC-SIGN is
expressed by human pulmonary DCs [7,14], and mycobac-
teria-derived antigens have been detected in DC-SIGN
þ DCs
in lymph nodes from patients with TB, suggesting that
interactions between the lectin and the bacillus may occur
during the natural course of infection [7].
In order to further our understanding of the role of DC-
SIGN in vivo, we have analysed the expression of the lectin in
broncho-alveolar lavage (BAL) cells from patients with TB, as
compared to cells from other patients.
Methods
Patients and Samples
Individuals studied (n¼74; mean age 17.6 6 19.3 y; median
age 10.5 y; 54% males) included patients with TB (n ¼ 40),
sarcoidosis (n¼11), or asthma (n¼14). Other individuals had
alveolar proteinosis (n ¼ 1), tracheal obstruction (n ¼ 1),
tracheal surgery (n¼1), inactive TB (n¼5), and lymphoma (n
¼ 1). These individuals (n ¼ 9) are considered as controls in
the rest of the study. All individuals were HIV negative and
non-smokers. None were receiving anti-mycobacterial ther-
apy and/or corticosteroids at the time of biopsy, except for
the treatment of asthma. TB was diagnosed by smear
observation and/or bacterial culture and/or clinical symp-
toms. Asthma was deﬁned as a history of recurrent wheezing
episodes and daily use of asthma medication. The diagnosis of
sarcoidosis was based on previously described criteria [16].
Inactive TB refers to patients who had a previous history of
TB (which was successfully treated) without reactivation. BAL
ﬂuids were performed as previously described [17] for
diagnostic purpose. Blood mononuclear cells from healthy
volunteers (Etablissement Franc ¸ais du Sang, Paris, France)
and from TB patients with smear observation were isolated by
Ficoll-Paque (Pharmacia, Uppsala, Sweden) centrifugation.
Only ﬂuids in surplus were used in this study, according to
institutional guidelines.
Alveolar M/s Isolation, Treatment, and Infection
BAL cells were washed and cultured in RPMI-1640
(Invitrogen, Carlsbad, California, United States) supple-
mented with 10% heat-inactivated foetal calf serum (FCS;
Dutscher, Brumath, France) and 2 mM L-glutamine in Petri
dishes for 1 h at 37 8C before removing nonadherent cells.
When required, cells were treated with IL-4 (10 ng/ml, R&D
Systems), tumor necrosis factor (TNF)-a (50 ng/ml; R&D
Systems, Minneapolis, Minnesota, United States), Escherichia
coli–derived LPS (100 ng/ml; Sigma, St. Louis, Missouri, United
States), or a green ﬂuorescent protein (GFP)-expressing strain
of M. tuberculosis H37Rv (pEGFP plasmid was a kind gift from
G. R. Stewart, University of Surrey, United Kingdom) at a
multiplicity of infection (MOI) of one bacterium per cell.
THP1 Cell
THP1 (ATCC TIB-202) cells were transduced with a
lentiviral DC-SIGN–encoding vector [18]. DC-SIGN–express-
ing cells were positively selected by ﬂow cytometry–based cell
sorting and cultivated, as THP1 cells, in RPMI-1640 supple-
mented with 10% heat-inactivated FCS and 2 mM L-
glutamine.
Flow Cytometry
Cells were treated and analysed as previously described [19].
The following monoclonal antibodies (mAbs) were used: anti-
CD11b-PE, anti-CD11c-PE, anti-CD16-PE, anti-CD32-PE, anti-
CD40-PE, anti-CD64-FITC, and anti-CD206-PE (all from
Beckman Coulter, Allendale, New Jersey, United States); anti-
CD1a-PE, anti-CD11b-APC, anti-CD14-PE, anti-CD83-PE,
anti-CD86-PE,anti-CD123-PE-Cy5,andanti–humanleukocyte
antigen (HLA)-DR-PE (all from BD Biosciences, San Diego,
California, United States); anti-CD209 (DC-SIGN)-FITC and
anti-PE (clone 120507; R&D Systems); anti-TLR2-PE, anti-
TLR4-PE, and anti-TLR9-PE (all from eBioscience, San Diego,
California, United States); and anti-BDCA-1-APC, anti BDCA-
2-PE,andanti-BDCA-3-PE(allfromMiltenyiBiotech,Bergisch
Gladbach, Germany).Isotype controls wereall purchased from
BD Biosciences. Fluorescence was analyzed using FACScalibur
and CellQuest Pro software (BD Biosciences).
Binding Experiments
Total BAL cells were pre-incubated for 30 min at 37 8C,
according to a previously published procedure [20], in RPMI-
1640 containing 10% FCS and eventually containing isotype
controls,eitheramixofPE-conjugatedandunconjugatedanti-
DC-SIGN antibodies (clones 120507 and 1B10, a kind gift from
A. Amara, Institut Pasteur, Paris, France) or a mix of APC-
conjugated and unconjugated anti-CD11b antibodies (clones
M1/70 [BD Biosciences] and 2LPM19c1 [Dako, Glostrup,
Denmark]). All antibodies were used at 10 lg/ml. Pre-
incubation at 37 8C in the presence of antibodies resulted in
partial internalization of the corresponding receptors but did
not decrease cell-associated ﬂuorescence, because a mix of
unlabelled and ﬂuorescently labelled antibodies was used
duringthisstep(datanotshown).Cellsweretheninfectedwith
GFP-expressing M. tuberculosis H37Rv, at a multiplicity of
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without phagocytosis. Cells were then washed in RPMI-1640
and further stained with PE-conjugated anti-DC-SIGN and
APC-conjugated anti-CD11b antibodies for 30 min at 4 8C.
Cells were then analyzed by ﬂow cytometry. Binding to THP1
and THP1::DC-SIGN cells was realized as previously described
for DC-SIGN–expressing HeLa cells [7]. Inhibition of binding
was realized using anti–DC-SIGN antibodies at 10 lg/ml.
Figure 1. Alveolar CD11b
þ Cells Over-Express DC-SIGN in Patients with TB
(A) BAL cells from a patient with TB (upper four panels) and from a patient with sarcoidosis (lower two panels) were analyzed by flow cytometry.
Expression of CD3 and CD4 was analyzed on cells from R1. CD11b and DC-SIGN expression was analyzed on cells from R2.
(B) Distribution of the proportion of CD11b
þDC-SIGN
þ cells in BALs according to pathology and age. Black circles indicate  15 y of age; black triangles
indicate  20 y; NC, no case.
(C) DC-SIGN (upper panels) and M. tuberculosis (lower panels) immunodetection in serial sections of a lung biopsy from a patient with TB. The pictures
are representative of results obtained with samples from a total of four patients. G, granuloma.
(D) DC-SIGN immunodetection in a lung biopsy from a patient with sarcoidosis. The pictures are representative of results obtained with samples from a
total of three patients.
In (C) and (D), magnification in left panels is 1003, and regions in squares are shown at higher magnification in right panels.
DOI: 10.1371/journal.pmed.0020381.g001
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BAL ﬂuids were centrifuged for 15 min at 1000 3 g and
supernatants were concentrated three to eight times using
Ultra-15 and YM-5 concentrators (Amicon; Millipore, Bill-
erica, Massachusetts, United States). Concentrated BAL ﬂuids
were analyzed for IL-4, IL-10, and IL-13 using high-sensitivity
enzyme-linked immunosorbent assay (ELISA) kits from R&D
Systems. The minimal detectable dose of IL-4, IL-10, and IL-
13 was 0.11 pg/ml, ,0.5 pg/ml, and ,32 pg/ml, respectively.
For analysis of alveolar M/ supernatants, M/s were cultured
in Petri dishes for 1 h before removing non-adherent cells.
Adherent cells were further incubated for 18 h in medium
with or without E. coli LPS (10 ng/ml, Sigma), LAM (10 lg/ml;
gift from G. Puzo, IPBS, Toulouse, France), anti-DC-SIGN
antibodies (50 lg/ml, clones 1B10 and 120507), and isotype
control (50 lg/ml). IL-10 in culture supernatant was then
measured by ELISA (high-sensitivity kit, R&D Systems).
Immunohistochemistry
Lung biopsies were stained for DC-SIGN and M. tuberculosis
using a DC-SIGN antibody (clone 1B10) and a homemade
anti-M. bovis BCG polyclonal rabbit serum, respectively, as
previously described [19].
Confocal Microscopy
M/s were allowed to adhere for 15 min on polylysine-
coated cover slips before ﬁxation. Cells were then permea-
bilized with 0.05% saponin, immunostained, and analysed as
described [19]. DC-SIGN was detected using clone 120507
mAb and a Cy3-conjugated secondary mAb (Amersham, Little
Chalfont, United Kingdom). Examination was realized using a
confocal microscope (Zeiss, Oberkochen, Germany) and the
software LSM 510 v3.2 (Zeiss).
RT-PCR
Cells were recovered and homogeneized in Trizol (GIBCO
BRL/Invitrogen, Carlsbad, California, United States). Total
RNAs were extracted by classical chloroform procedure.
Puriﬁed RNAs (100 ng) were used to amplify the DC-SIGN
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
transcripts using the Onestep RT-PCR kit (Qiagen, Valencia,
California, United States). Oligonucelotides hCD209F (59-
ATTTTC CAACTCATTTTCAGCC-39) and hCD209R (59-
TCTCACAGAAAGAGGAGGACAC-39) were used to amplify
a 193-base pair product in the exon 7 of DC-SIGN.
Oligonucelotides GAPDHRT1 (59-GAGTCAACG
GATTTGGTCGTAT-39)a n dG A P D H R T 2( 5 9-
AGTCTTCTGGGTGGCAGTGAT-39) were used to amplify a
542-base pair product from exons 2 to 8 of GAPDH. Reverse
transcriptionwasconductedfor30minat508C.PCRconsisted
of 15-min activation (95 8C), and 35 cycles of 1-min denatura-
tion (94 8C), 1-min annealing (55 8C), and 1-min elongation (72
8C). RT-PCR products were analyzed on a 1% agarose gel.
Results
Alveolar CD11b-Expressing Cells Over-Express DC-SIGN in
Patients with TB
Given the important role of DC-SIGN in mycobacterial
interactions with human MoDCs in vitro [7–9], we asked
whether the lectin might interact with the tubercle bacillus
during the natural course of TB in vivo in the lungs. Flow
cytometry analysis of BAL cells from TB patients typically
showed two major cell populations (Figure 1A, upper left
panel). One of them, noted as R1, essentially consisted of
CD3
þ and either CD4
þ or CD4
  T lymphocytes (Figure 1A,
upper right panel). Cells from the other major population,
noted as R2, were all CD3
  (data not shown). Total cells were
co-stained with antibodies directed against CD11b (type 3
complement receptor [CR3] a chain) and DC-SIGN. Cells
from R2 were all CD11b
þ (Figure 1A, middle left panel). In
patients with TB, a variable proportion of this cell population
was DC-SIGN
þ (27% in the patient shown in Figure 1A,
middle right panel). By contrast, R2 cells from patients
without TB were nearly all CD11b
þDC-SIGN
  (results
obtained with BAL cells from a patient with sarcoidosis are
shown in Figure 1A, lower left and right panels). Results
obtained for all individuals included in the study are shown in
Figure 1B. The proportion of CD11b
þDC-SIGN
þcells in BALs
was not correlated with gender (19.8 6 20.0% in males vs.
16.3 6 13.7% in females; Mann-Whitney test p ¼ 0.786), and
very weakly with age, as assessed by Spearman correlation
coefﬁcient (qs
2¼0.094, p¼0.0078), which most likely reﬂected
the bias in population sizes depending on age and pathology.
Indeed, 72% of the whole population was aged  15 y and
included 85% of the total TB cases. When the whole
population was divided in individuals of  15 or  20 y of
age, correlation with age was no longer observed (qs
2¼0.003,
p ¼ 0.813, and qs
2 ¼ 0.0002, p ¼ 0.777, respectively). By
contrast, the proportion of CD11b
þDC-SIGN
þ cells in BALs
was highly related to the pathology. Indeed in patients with
TB, 11%–71% of CD11b
þ cells (31.2 6 13.4%) were found to
express the lectin. By contrast, CD11b
þ cells from patients
with other lung diseases or from control individuals barely
expressed DC-SIGN (2.9 6 1.8% in patients with asthma,
Mann-Whitney test p , 10
 7; 3.7 6 4.1% in patients with
sarcoidosis, Mann-Whitney test p , 10
 6; 1.9 6 2.0% in other
individuals, Mann-Whitney test p , 10
 5; all as compared to
the group of patients with TB). Immunohistochemistry
analysis of lung biopsy samples from patients with TB (n ¼
4) revealed that DC-SIGN
þ cells localized mostly in cellular
inﬁltrates outside granulomas and were tightly associated
with bacilli (representative result from one patient is shown
in Figure 1C). By contrast, and in accordance with results
from ﬂow cytometry, very few DC-SIGN–expressing cells were
detected inside and outside granulomas in lung biopsy
Figure 2. Alveolar DC-SIGN
þ Cells in Patients with TB Are M/s
(A) Total BAL cells from a patient with TB were allowed to adhere to the plastic for 1 h at 37 8C in complete medium. CD11b and DC-SIGN expression
was analyzed by flow cytometry before (left) and after (right) adherence.
(B) Surface and intracellular DC-SIGN (red) expression by an adherent alveolar cell examined under the confocal microscope.
(C) Flow cytometry analysis of surface expression of BDCA-1 (CD1c), BDCA-2, BDAC-3, CD1a, CD11b, CD11c, CD14, CD68, CD83, and CD123 in DC-SIGN
þ
BAL cells from a patient with TB.
(D) Flow cytometry analysis of surface expression of CD40, CD86, HLA-DR, CD11b, CD11c, CD206, CD16, CD32, CD40, CD64, TLR2, TLR4, and TLR9 in DC-
SIGN
þ BAL cells from a patient with TB.
In (C) and (D), analysis was performed on DC-SIGN–expressing cells in R2, as shown in Figure 1.
DOI: 10.1371/journal.pmed.0020381.g002
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DC-SIGN in Human Tuberculosissamples from patients with sarcoidosis (n ¼ 3; representative
result from one patient is shown in Figure 1D).
Alveolar DC-SIGN–Expressing Cells in Patients with TB Are
M/s
The ability of CD11b
þDC-SIGN
þ BAL cells to bind to the
plastic (Figure 2A), together with their morphology (Figure
2B), strongly suggested a M/ phenotype. In order to precisely
deﬁne this phenotype, BAL cells from patients with TB were
stained for DC-SIGN and for a number of markers speciﬁc to
various DC subtypes, monocytes, and M/s, and were analyzed
by ﬂow cytometry (Figure 2C and 2D). Four DC subtypes have
been described in the human lungs [21], namely myeloid DCs
type 1 (MDC1) expressing BDCA-1 and HLA-DR, myeloid DCs
type 2 (MDC2) which are BDCA-3
hiHLA-DR
þCD32
 CD64
 ,
plasmacytoid DCs (pDCs) expressing BDCA-2 and CD123, and
CD1a
þ Langerhans cell type DCs. As shown in Figure 2C and
2D, DC-SIGN–expressing cells were clearly negative for
BDCA-1 and BDCA-2. Cells were also BDCA-3
loCD32
þCD64
þ,
and they were negative for the Langerhans cell markers CD1a
and CD207 (langerin; data not shown). Finally the cells did not
express the DC maturation marker CD83. It is thus very
unlikely that these cells constitute either myeloid or plasma-
cytoid DCs [21]. Cells were also negative for the monocyte
marker CD14 (Figure 2C). However, the cells expressed the
myeloid marker CD68 (Figure 2C). Additional staining helped
to further deﬁne the phenotype of these cells. Indeed DC-
SIGN
þ cells in R2 (see Figure 1A) clearly expressed the co-
stimulation and presentation molecules CD40, CD86 (B7–2),
and HLA-DR, as well as the antigen uptake molecules CD11b,
CD11c (CR4 a chain), CD206 (mannose receptor), CD16
(FccRIII), CD32 (FccRII), CD64 (FccRI), and the Toll-like
receptors (TLRs) TLR2, TLR4, and TLR9. Altogether, these
results indicate that the CD11b
þDC-SIGN
þ cells observed in
BALs from patients with TB most likely constitute alveolar
M/s. Furthermore, DC-SIGN
þ and DC-SIGN
  CD11b
þ alveo-
lar M/s were found to express HLA-DR and CD86 at similar
levels (data not shown), indicating that DC-SIGN expression
by these cells did likely not result from cell activation.
DC-SIGN Is Induced on Resident Alveolar M/s upon M.
tuberculosis Infection
We next sought to address whether the DC-SIGN
þ M/s
detected in BALs from patients with TB were resident
Figure 3. DC-SIGN Is Induced on Resident Alveolar M/s upon M. tuberculosis Infection
(A) Flow cytometry analysis of CD11b and DC-SIGN expression by PBMCs from a healthy donor (upper panels) and a patient with TB (lower panels).
(B) Adherent DC-SIGN
  alveolar M/s from a non-tuberculous patient were infected with a GFP-expressing strain of M. tuberculosis at a MOI of one
bacterium per cell, or treated with IL-4, TNF-a, or LPS, or left untreated (ø; control). After 48 h at 37 8C, cells were recovered and DC-SIGN expression was
analyzed by flow cytometry. In M. tuberculosis panel, the grey area corresponds to GFP
þ (infected) cells, and the plain line corresponds to GFP
 
(uninfected) cells.
(C) Cells infected with M. tuberculosis at a MOI of 1 for 1, 2, 4, or 24 h were analysed by RT-PCR for DC-SIGN and GAPDH mRNAs.
DOI: 10.1371/journal.pmed.0020381.g003
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DC-SIGN in Human Tuberculosisalveolar M/s or were derived from DC-SIGN
þ monocytes
recruited from the circulation during infection. Peripheral
blood mononuclear cells (PBMCs) from patients with TB (n¼
3) were analysed for DC-SIGN expression by ﬂow cytometry.
DC-SIGN could be detected neither in these cells nor in
PBMCs from healthy blood donors (results from one
representative experiment is shown in Figure 3A). To assess
the induction hypothesis, DC-SIGN
  alveolar M/sw e r e
puriﬁed by adherence from patients with asthma (n ¼ 3).
Cells were then infected with M. tuberculosis at a MOI of 1
bacterium/cell, or treated with IL-4, TNF-a,o rE. coli–derived
LPS. IL-4 was used as a control because this cytokine has been
shown to induce DC-SIGN expression in human monocytes
[22]. TNF-a was used to assess whether an inﬂammatory
context, like the one encountered in lungs from patients with
TB, could induce DC-SIGN. Finally, LPS was included in
order to assess whether TLR ligation may result in DC-SIGN
induction, as recently reported in human circulating blood
monocytes [23]. Flow cytometry analysis after 48 h showed a
marked expression of DC-SIGN on the surface of the cells,
both when infected with M. tuberculosis and when treated with
IL-4, as compared to untreated cells (Figure 3B). By contrast,
neither TNF-a- nor LPS-treated cells were found to express
the lectin. Interestingly, in cells infected with a GFP-
expressing strain of M. tuberculosis, both GFP
þ (infected) and
GFP
 (uninfected) cells were found DC-SIGN
þ, indicating that
DC-SIGN induction likely relies on a soluble factor secreted
by the host and/or the pathogen and that has yet to be
identiﬁed. RT-PCR analysis of the DC-SIGN transcript at
various times post-infection (Figure 3C) further conﬁrmed
that M. tuberculosis infection induces DC-SIGN expression in
resident alveolar M/s as soon as 1 h after infection. Because
IL-4 and IL-13 were previously shown to induce DC-SIGN
expression in monocytes [22], we wished to assess whether
these cytokines might account for DC-SIGN expression by
alveolar M/s in vivo in the lungs of patients with TB. We
collected BAL ﬂuids from a number of patients with TB or
with other pathologies, and we measured IL-4 and IL-13
amounts by ELISA. IL-4 was detected in some samples, but
without any apparent correlation with either the pathology
or the amount of DC-SIGN-expressing alveolar M/s in the
corresponding samples (Table 1). IL-13 was not detectable in
all samples tested (data not shown). This indicates that IL-4
and IL-13 are likely not responsible for DC-SIGN induction
in vivo in the lungs of M. tuberculosis–infected patients.
DC-SIGN Mediates M. tuberculosis Binding to Alveolar M/s
from Patients with TB
We next wished to evaluate the possible functional
consequences of DC-SIGN induction in alveolar M/si n
patients with TB. DC-SIGN has previously been shown to be
a major M. tuberculosis receptor on human MoDCs [7]. We
thus evaluated lectin’s contribution to mycobacterial bind-
ing to and entry into DC-SIGN
þ alveolar M/s. Total BAL
cells from two patients with TB were incubated with a GFP-
expressing strain of M. tuberculosis for 4 h at 4 8C in the
presence or absence of blocking anti-CD11b (CR3) or anti–
DC-SIGN or control isotype antibodies. The cells were
stained for CD11b and DC-SIGN using phycoerythrin- or
allophycocyanin-conjugated antibodies. Flow cytometry
analysis revealed that among CD11b
þ alveolar M/s, DC-
SIGN–expressing cells were much more prone to infection
than their DC-SIGN
  counterparts. After infection, almost
80% of CD11b
þDC-SIGN
þ versus only 20% of CD11b
þDC-
SIGN
  cells were found GFP
þ (Figure 4A and 4B).
Accordingly, anti-DC-SIGN antibodies could inhibit .60%
of M. tuberculosis binding to DC-SIGN–expressing M/s
(Figure 4A and 4B). The antibodies had a slight positive
effect on mycobacterial binding to CD11b
þDC-SIGN
  cells,
which was likely due to more mycobacteria available for
binding to these cells in the presence of the antibody
(Figure 4A and 4B). Conversely, anti-CD11b antibodies
could inhibit M. tuberculosis binding to DC-SIGN
  alveolar
M/s of almost 50% in average, whereas they had only a
very minor effect on binding to CD11b
þDC-SIGN
þ cells
(Figure 4A and 4B). In order to conﬁrm that DC-SIGN
constitutes a major M. tuberculosis receptor in the context of
aM / cell and in the presence of other mycobacterial
receptors, THP1 human M/s were transduced with a
lentivirus-based DC-SIGN-encoding vector and were used
in M. tuberculosis–binding experiments. M. tuberculosis was
f o u n dt ob i n dt oD C - S I G N – e x p r e s s i n gT H P 1M /sb y
greater than 10-fold more than to THP1 cells (Figure 4C).
Anti-DC-SIGN antibodies could fully inhibit mycobacterial
binding to DC-SIGN-expressing cells, whereas they had
virtually no effect on binding to THP1 cells. Altogether,
these results indicate that DC-SIGN expression renders
M/s, and in particular alveolar M/s in the lungs of patients
with TB, more susceptible to infection than their DC-SIGN
 
counterparts. Confocal microscopy examination of alveolar
M/si n f e c t e dw i t hG F P - e x p r e s s i n gM. tuberculosis and
subsequently immunostained for DC-SIGN, showed, as in
MoDCs [7], a marked recruitment of the lectin at the site of
bacterial attachment and in the nascent phagosome (Figure
4D, upper and middle panels), followed by exclusion of the
receptor from the mycobacterial vacuole once the bacillus
was engulfed, most likely as a result of receptor recycling
(Figure 4D, lower panels).
DC-SIGN Does Not Mediate IL-10 Secretion in Alveolar
M/s
Besides its function in pathogen recognition and phag-
ocytosis, DC-SIGN has been proposed to play a role in
triggering intracellular signals and cytokine secretion. In
particular, it has previously been reported that DC-SIGN
ligation by LAM synergizes with TLR4 ligation by LPS to
potentiate IL-10 secretion by MoDCs [8]. We sought to
determine whether this might also be the case in alveolar
Table 1. IL-4 in BAL Fluids Does Not Correlate with Pathology
nor with Amount of DC-SIGN-Expressing Alveolar M/s
Pathology IL-4 (pg/ml) Percent DC-SIGN
þ M/
Mean 6 SD Range Mean 6 SD Range
Control (n ¼ 3) 0.28 6 0.04 0.24–0.32 1.67 6 0.47 1–2
Asthma (n ¼ 6) 2.28 6 1.55 (ND ¼ 3) 0.24–4.05 2.50 6 1.60 0–4
Sarcoidosis (n ¼ 3) 0.27 6 0.02 0.24–0.29 0.33 6 0.47 0–1
TB (n ¼ 15) 0.28 6 0.09 0.20–0.60 34.87 6 13.36 18–71
BALs were centrifuged and supernatants were concentrated three to eight times. Concentrates were used in ELISA
for IL-4 detection. The minimal detectable dose was 0.11 pg/ml. In parallel, BAL cells from the corresponding
samples were analyzed by flow cytometry to quantify the percentage of DC-SIGN–expressing alveolar M/s.
ND ¼ 3, not detected in three patients; SD, standard deviation.
DOI: 10.1371/journal.pmed.0020381.t001
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from three patients with TB were puriﬁed by adherence and
stimulated for 18 h with LPS alone or LPS and M. tuberculosis–
derived LAM, in the presence or absence of anti-DC-SIGN or
control isotype antibodies. Although basal IL-10 production
differed among M/ preparations, treatment of the cells with
LPS resulted in a slight increase in IL-10 secretion in all cases,
as revealed by ELISA (Table 2). Treatment of the cells with
LAM alone had virtually no effect on IL-10 production. By
contrast with what has been reported in MoDCs [8], LAM did
clearly not synergize with LPS to induce production of the
cytokine by alveolar M/s (Table 2). This was conﬁrmed by
measuring IL-10 in BAL ﬂuids from patients with TB or with
other pathologies (Table 3). IL-10 was detected in some
samples but not systematically in samples from patients with
TB that contained DC-SIGN-expressing M/s.
Figure 4. DC-SIGN Mediates M. tuberculosis Binding to Alveolar M/s from Patients with TB
(A) Alveolar M/s from a patient with TB were infected with GFP-expressing M. tuberculosis, in the absence (ø; upper left panel) or the presence of
control isotype (upper right panel), anti-CD11b (lower left panel), or -DC-SIGN (lower right panel) blocking antibodies. In the upper panels, cells were
then stained with fluorescent PE-conjugated anti-DC-SIGN and APC-conjugated anti-CD11b antibodies. In lower panels, fluorescent antibodies were
added together with blocking antibodies (same clones).
(B) Proportion of GFP
þcells in DC-SIGN
 (open bars) and DC-SIGN
þ(grey bars) alveolar M/s as calculated from (A) using BALs from two patients with TB.
THP1 M/s expressing or not expressing DC-SIGN (THP1::DC-SIGN) were used in a binding experiment with M. tuberculosis H37Rv, in the presence or
absence of anti-DC-SIGN antibodies.
(D) Confocal microscopy examination of adherent DC-SIGN
þ cells infected with GFP-expressing M. tuberculosis for various times.
DOI: 10.1371/journal.pmed.0020381.g004
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Our study reveals the presence of a novel DC-SIGN–
expressing subset of alveolar M/s in the lungs of patients with
TB. In patients with TB, this M/ subset represents up to 70%
of total CD11b
þ M/s. By contrast, in other patients with non-
tuberculous lung diseases, as well as in control individuals,
DC-SIGN M/s represent only 3% on average of CD11b
þM/s.
Our results strongly suggest that DC-SIGN
þ M/s arise from
induction of the DC-SIGN gene during infection. IL-4 and IL-
13, two cytokines known to induce DC-SIGN expression in
monocytes [22], are unlikely to account for DC-SIGN
expression by alveolar M/s in patients with TB, because
these cytokines were either not detected (IL-13) or detected
in variable amounts and independently of pathology (IL-4) in
BAL ﬂuids from a number of different patients. Recently, DC-
SIGN induction has been demonstrated in human circulating
blood monocytes treated with TLR agonists [23]. This is
unlikely to be the case here because we have shown that LPS
treatment of DC-SIGN
  alveolar M/s obtained from individ-
uals without TB could not induce DC-SIGN expression in
these cells (see Figure 3B). Inﬂammation alone is unlikely to
induce DC-SIGN, because alveolar M/s from patients with
asthma or sarcoidosis were mostly DC-SIGN
 , whereas these
diseases are characterized by a marked inﬂammatory re-
sponse in the lungs. The fact that both M. tuberculosis–infected
and uninfected alveolar M/s up-regulate DC-SIGN during ex
vivo infection (see Figure 3B) is of interest, as it strongly
suggests that soluble factor(s) from the host and/or the
microbe can induce DC-SIGN in bystander DC-SIGN
  M/s.
These factors will have to be deﬁned in future studies. In
particular, the role of M. tuberculosis–derived lipids and
proteins that are secreted by the bacterium prior to uptake
by host cells and from inside infected cells [24,25] will have to
be investigated. In addition, the possible role of host factors,
such as IL-15, will have to be examined in this respect. Indeed,
IL-15 has recently been shown to induce DC-SIGN expression
in human monocytes in vitro [23], and alveolar M/s from
patients with TB have been reported to produce this cytokine
ex vivo [26].
So far, mycobacterial receptors on M/s have been mostly
characterized using model M/s, namely mouse bone marrow–
derived or human monocyte–derived M/s [27]. Very few
reports are available on mycobacterial receptors on alveolar
M/s, and all of them used cells from healthy individuals or
laboratory animals. The main mycobacterial receptors
identiﬁed on human alveolar M/s are CRs, especially CR4
and CR3 on human cells [28–30], the surfactant protein A
receptor [31], and the mannose receptor [32]. Other studies in
murine alveolar M/s conﬁrmed these ﬁndings and added
other receptors, such as scavenger receptors, to the list [33].
However, to our knowledge, ours is the ﬁrst study of M.
tuberculosis receptors on alveolar M/s in patients with TB. Our
results suggest a novel scenario of alveolar M/ infection
during TB. In this scenario, CRs likely mediate most of cell
infection in a naive host, and DC-SIGN–expressing M/s
become privileged target cells for the bacillus once the
infection is established. Furthermore, DC-SIGN induction in
bystander cells may be of advantage for the tubercle bacillus
to increase its intracellular territory inside the infected host.
Apart from pathogen binding, DC-SIGN may play a role in
signal transduction. In particular, DC-SIGN ligation by the
mycobacterial lipoglycan LAM has been reported to poten-
tiate TLR-4–mediated IL-10 secretion by LPS-stimulated
MoDCs [8]. However, treatment of LPS-stimulated alveolar
M/s with LAM did not result in an increase of IL-10
production, which remained relatively low in both stimulated
and untreated cells. Moreover, IL-10 was not detected in BAL
ﬂuids from patients with TB (Table 3). This is in accordance
with previous studies reporting that IL-10 is detected in
comparable amounts in BALs and lung biopsies from TB
patients, and from healthy individuals [34]. IL-10 production
is known to be low in M/s as compared to in DCs. The
discrepancy between our results, that show no role of DC-
SIGN in IL-10 secretion, and those from Geijtenbeek et al. [8],
who reported such a role, likely relies on the different cell
types used in the two studies. Our results do not exclude the
possibility that DC-SIGN may participate in IL-10 production
by DCs in patients with TB, especially in the lymph nodes.
This possibility will have to be further explored and may have
important local consequences, including down-modulation of
the local inﬂammation due to infection, either directly or by
driving T lymphocytes toward a regulatory phenotype [35,36].
Table 2. DC-SIGN Ligation by LAM Does Not Potentiate IL-10 (in pg/ml) Production by LPS-Stimulated Alveolar M/s
Patient Number Untreated LPS LAM LPS/LAM LPS/LAM/Anti-DC-SIGN LPS/LAM/Isotype
14 6 6 1.1 76 6 1.4 50 6 0.4 80 6 0.7 74 6 1.8 ND
26 6 6 0.2 70 6 0.9 60 6 2.3 67 6 0.5 67 6 0.9 68 6 0.7
32 2 4 6 1.1 298 6 1.4 216 6 0.2 280 6 0.7 220 6 1.8 ND
Alveolar M/s from three patients with TB were treated for 18 h at 37 8C with 10 ng/ml LPS and 10 lg/ml LAM in the presence or absence of anti-DC-SIGN or control isotype antibodies. IL-10 secretion was measured in the cell culture
supernatant by ELISA (expressed in pg/ml).
ND, not detected.
DOI: 10.1371/journal.pmed.0020381.t002
Table 3. IL-10 Is Not Detected in BAL Fluids from Patients with
TB
Pathology Mean 6 SD Range
Control (n ¼ 3) (ND ¼ 3) ND
Asthma (n ¼ 6) 8.06 6 6.18 (ND ¼ 3) 0.64–15.9
Sarcoidosis (n ¼ 3) 15.86 (ND ¼ 2) 15.86
a
TB (n ¼ 4) (ND ¼ 4) ND
BAL fluids were treated as in Table I. IL-10 (in pg/ml)was measured by ELISA and the minimal detectable dose was
,0.5 pg/ml.
an ¼ 1.
ND, not detected; ND ¼ [number], not detected in [number] patients; SD, standard deviation.
DOI: 10.1371/journal.pmed.0020381.t003
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DC-SIGN in Human TuberculosisIn conclusion, our study reveals that during the natural
course of TB in human lungs, soluble host and/or mycobac-
terial factor(s) induce DC-SIGN expression by alveolar M/s,
which renders the cells highly prone to infection by the
tubercle bacillus. DC-SIGN induction in alveolar M/s may
have important consequences on lung colonization by M.
tuberculosis, as well as on host immune and inﬂammatory
responses, which will require further investigation in cell and
animal models, as well as in patients with TB.
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DC-SIGN in Human TuberculosisPatient Summary
Background Tuberculosis (TB) is one of the most common major
infectious disease today. It is estimated that two billion people—or one-
third of the world’s population—are chronically infected without active
symptoms. Nine million new cases of active disease are diagnosed
annually, resulting in two million deaths, mostly in developing countries.
TB is predominantly a lung disease. It is caused by a microbe called
Mycobacterium tuberculosis, which infects lung cells. Patients with active
disease easily infect others through coughing, sneezing, and spitting.
Why Was This Study Done? Most of what we know about how
Mycobacterium infects lung cells during the early stages of TB comes
from animal studies or studies in healthy volunteers. In this study, the
researchers wanted to examine whether lung cells from patients with TB
were different from those of healthy people or those with different lung
diseases, and what this might tell us about the way the infection spreads
in the lung. In particular, they looked at the surface of the lung cells,
because this is the part directly involved in the first contact with
Mycobacterium.
What Did the Researchers Do and Find? They studied 74 individuals:
40 had TB, 25 had other inflammatory lung diseases, and nine had
neither active TB nor lung inflammation and served as healthy
‘‘controls.’’ The patients underwent a procedure (called bronchoalveolar
lavage) that washes out some of the secretions and cells from the lower
respiratory tract. The researchers then analysed the cells in different
ways. They concentrated on a type of cell called a macrophage (the
natural target of Mycobacterium) and found that macrophages from
patients with TB had much more of a particular protein called DC-SIGN
on their surface than macrophages from patients with other diseases or
from the control individuals. They then took macrophages from a control
individual (which thus had very low levels of DC-SIGN) and infected them
with Mycobacterium under laboratory conditions. The researchers found
that shortly after infection, not only the infected cells but also some of
their neighbours started to display DC-SIGN on their surface. The
researchers also found that having DC-SIGN on the surface made
uninfected cells much more susceptible to infection.
What Does This Mean? The results suggest that DC-SIGN has an
important function in amplifying TB infection in the lung. In the long run,
understanding how Mycobacterium infects patients and either makes
them ill or establishes a chronic infection without acute symptoms
should help with the development of new or better ways to prevent
infection or treat disease.
Where Can I Find More Information Online? The following Web sites
provide information on tuberculosis.
World Health Organization pages on TB:
http://www.who.int/tb/en/
TB Vaccine Cluster page:
http://www.tb-vac.org
Tuberculosis.net, a source for TB teaching materials:
http://www.tuberculosis.net/
Wikipedia pages on TB:
http://en.wikipedia.org/wiki/Tuberculosis
MedlinePlus pages on TB:
http://www.nlm.nih.gov/medlineplus/tuberculosis.html
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